Structure Therapeutics Inc. Stock Prediction and Forecast [GPCR]

AI-generated source summary

This analysis for Structure Therapeutics (GPCR) reports a strong buy signal since September 16, 2025, with a score of 7.39. The stock has gained 8.21% in the past four days, averaging 2.05% daily. The analyst expects the 3-month trend may change to 3.15%, with a possible range from -27.63% to 3.15%. A 12-month analysis projects a -53.78% change, ranging from -92.01% to -62.60%. The stock ended the last trading day at $23.58, rising 1.51%, with a 4.14% fluctuation. The 52-week range is $13.22 to $45.37. Recent news indicates sensitivity to market dynamics, and they are awaiting studies results. The overall recommendation for analyst sources is to sell. Some signals for signals includes bullish pivot and Bollinger signals, the recommenced stop loss is $22.74. Earnings are to be given on Nov. 12.

AI-generated summary based on the source content.

Evidence and evaluation progress

1. Original source published

   20 Sept 2025, 03:31 UTC

   The analyst published the original source item.

2. First prediction resolved

   22 Sept 2025, 13:30 UTC

   The first evaluable outcome in this case reached a terminal result.

3. Case evaluation completed

   22 Sept 2025, 13:30 UTC

   All evaluable predictions in this case reached terminal outcomes.

4. Source recorded by Tahlil Plus

   18 May 2026, 20:23 UTC

   The public source was preserved as the evidence record for this case.

5. Market predictions extracted

   18 May 2026, 20:47 UTC

   1 eligible signal linked to this case.

6. Outcome tracking started

   02 Jul 2026, 02:11 UTC

   Tahlil Plus began monitoring the extracted predictions.